肌内注射氯氮平用于治疗抵抗性精神病起始与维持治疗的回顾性研究
该回顾性研究评估了肌内注射氯氮平在治疗抵抗性精神病患者中起始和维持治疗的临床效果。
要点
- 肌内注射氯氮平可使92%初始不依从患者成功过渡到口服维持。
- 2年停药率24%,1年出院后停药率21%,均低于口服对照组。
- 停药风险降低无统计学显著性(HR 0.39,95%CI 0.14-1.06)。
核心结论
- 肌内注射氯氮平处方使初始不依从的治疗抵抗性精神病患者成功过渡到口服维持治疗。
- 停药率与仅口服氯氮平的患者相似,并与现有文献相当。
研究设计与样本
- 回顾性临床有效性研究,纳入3年期间接受肌内注射氯氮平处方的治疗抵抗性精神病患者39例。
- 对照组为仅口服氯氮平处方的162例患者,使用倾向评分处理适应证混杂。
主要发现
- 39例中19例至少接受一次注射,20例在强制选择下接受口服氯氮平。
- 2年随访中8例停用口服氯氮平,对照组162例中83例停药(停药率分别为24%和50%)。
- 出院后1年停药率分别为21%和44%。
- 肌内注射处方与2年停药风险非显著降低相关(HR 0.39,95%CI 0.14-1.06),出院后1年亦非显著(HR 0.37,95%CI 0.11-1.24)。
关键数值与推荐
- 主要结局为肌内注射处方后成功起始口服氯氮平。
- 次要结局包括起始后2年及出院后1年全因氯氮平停药。
- 唯一报告的肌内注射剂型特定不良事件为注射部位疼痛和肿胀。
临床怎么用
- 对于因精神病性症状导致口服不依从的治疗抵抗性精神病患者,可考虑肌内注射氯氮平以促进口服起始和维持。
- 肌内注射氯氮平处方后仍应监测停药风险,尤其出院后第一年。
局限性
- 回顾性设计,样本量较小(肌内注射组39例)。
- 停药风险降低无统计学显著性,置信区间宽。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clozapine is uniquely effective in treatment-resistant psychosis but remains underutilised, partly owing to psychotic symptoms leading to non-adherence to oral medication. An intramuscular formulation is available in the UK but outcomes remain unexplored. AIMS: This was a retrospective clinical effectiveness study of intramuscular clozapine prescription for treatment initiation and maintenance in treatment-resistant psychosis over a 3-year period. METHOD: Successful initiation of oral clozapine after intramuscular prescription was the primary outcome. Secondary outcomes included all-cause clozapine discontinuation 2 years following initiation, and 1 year after discharge. Discontinuation rates were compared with a cohort prescribed only oral clozapine. Propensity scores were used to address confounding by indication. RESULTS: Among 39 patients prescribed intramuscular clozapine, 19 received at least one injection, whereas 20 accepted oral clozapine when given an enforced choice between the two. Thirty-six (92%) patients successfully initiated oral clozapine after intramuscular prescription; three never transitioned to oral. Eight discontinued oral clozapine during the 2-year follow-up, compared with 83 out of 162 in the comparator group (discontinuation rates of 24% and 50%, respectively). Discontinuation rates at 1-year post-discharge were 21%, compared with 44% in the comparison group. Intramuscular clozapine prescription was associated with a non-significantly lower hazard of discontinuation 2 years after initiation (hazard ratio 0.39, 95% CI 0.14-1.06) and 1 year after discharge (hazard ratio 0.37, 95% CI 0.11-1.24). The only reported adverse event specific to the intramuscular formulation was injection site pain and swelling. CONCLUSIONS: Intramuscular clozapine prescription allowed transition to oral maintenance in an initially non-adherent cohort. Discontinuation rates were similar to patients only prescribed oral clozapine and comparable to existing literature.
引用
- Casetta C, Oloyede E, Whiskey E, et al. A retrospective study of intramuscular clozapine prescription for treatment initiation and maintenance in treatment-resistant psychosis. Br J Psychiatry. 2020. PMID: 32605667. doi:10.1192/bjp.2020.115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。